Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6201192 | Ophthalmology | 2015 | 10 Pages |
Abstract
Level I evidence indicates that intravitreal anti-VEGF pharmacotherapy is safe and effective over 2 years for ME associated with CRVO and that delay in treatment is associated with worse visual outcomes. In addition, level I evidence demonstrates short-term efficacy of intravitreal corticosteroid but also an association with a higher frequency of adverse events.
Keywords
IVBpars plana vitrectomyBCVACRVORVOPRNVTEBRVOiOpCFTPPVIntravitreal triamcinoloneIVTIntravitreal bevacizumabCStMacular edemaLCABranch retinal vein occlusionRetinal vein occlusionCentral retinal vein occlusionOctbest-corrected visual acuityOptical coherence tomographyVisual acuityNEIRONcentral subfield thicknesscentral foveal thicknesspro re nataVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Intraocular pressureNational Eye InstituteScoreHORIZONCruiseCopernicusGalileo
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Steven MD, Stephen J. MD, Allen C. MD, Scott D. MD, Sophie J. MD, Justis P. MD, Jennifer E. MD, PhD,